NCT00703586已完成1 期
A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- MMC HIV RNA
研究概览
简要总结
Hypothesis: Intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication, particularly in the gastrointestinal mucosa with resultant reduction in markers of immune activation and improved GI immune reconstitution.
详细描述
- DURATION: Subjects will participate for a minimum of 28 weeks.
- SAMPLE SIZE: 18 subjects randomized 2:1 continued ARVs plus maraviroc versus continued ARVs plus additional ARV to be determined based on baseline ARV regimen.
- REGIMEN: At entry, subjects will be randomized to one of the following in a 2:1 ratio:
ARM A:
Intensification with maraviroc for 24 weeks at one of the following doses:
- 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
- 600 mg orally BID when coadministered with efavirenz or nevirapine
ARM B
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented treatment with combination antiviral therapy (ARV) during acute and early HIV-1 infection defined as:
- •Negative ELISA/Western Blot or indeterminate Western Blot in the presence of HIV-1 RNA>5,000 copies/ml
- •Positive HIV-1 serology with a detuned ELISA O.D. value below 1.0
- •A documented negative serology within 180 days of screening and a positive HIV-1 serology at screening
- •Treatment for at least one year with ARVs
- •Plasma HIV-1 RNA levels below detection for at least 6 months
- •CCR5 tropic virus pretreatment using the Monogram assay
- •GI biopsy at study entry
- •Agree to subsequent GI biopsy at 12 and 24 weeks
- •Laboratory values obtained within 45 days prior to study entry.
- •Absolute neutrophil count (ANC) ≥500/mm³
- •Hemoglobin ≥9.0 g/dL
- •Platelet count ≥80,000/mm³
- •AST (SGOT), ALT (SGPT), and alkaline phosphatase < 5.0 x ULN
- •Total bilirubin ≤ 2.5 X ULN if not on atazanavir containing regimen
- •PT/PTT within 1.5 control
- •Calculated creatinine clearance ≥60 mL/min as estimated by the Cockcroft Gault equation:
- •For men, (140 - age in years) x (body weight in kg) / (serum creatinine in mg/dL x 72) = CrCl (mL/min)
- •For women, multiply the result by 0.85 = CrCl (mL/min) NOTE: A program to assist in calculations is available on the DMC web site at: http://www.fstrf.org/ACTG/ccc.html
- •For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to initiating study medications unless otherwise specified by product labeling.
- •Female candidates of reproductive potential is defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) or have not undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation).
- •Contraception requirements:
- •Female candidates of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree that they will use at least one reliable method of contraception while receiving the protocol-specified drugs and for 6 weeks after stopping the medications.
- •Male Candidates: If you are a heterosexual male, you and your sexual partner must agree to use acceptable methods of birth control during the entire study. Acceptable methods of birth control include intrauterine device (IUD), diaphragm with spermicide,condoms or not having sex. Oral contraceptives alone are not an acceptable method of birth control.
- •Men and women age ≥18 years.
- •Participants must be HLA-B5701 negative if not taking abacavir as part of their regimen.
- •Ability and willingness of subject to give written informed consent.
排除标准
- •Currently breast-feeding.
- •Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry. NOTE: Subjects receiving stable physiologic glucocorticoid doses, defined as prednisone ≤ 10 mg/day, will not be excluded.
- •Known allergy/sensitivity to study drugs or their formulations.
- •Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- •Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry.
- •Pretreatment viral population that is either dual mixed tropic or X4 tropic using the Monogram assay
- •Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness.
- •Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the requirements.
研究组 & 干预措施
1
Experimental
ARM A:
Intensification with maraviroc for 24 weeks at one of the following doses:
- 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
- 600 mg orally BID when coadministered with efavirenz or nevirapine
干预措施: Maraviroc (Drug)
2
Active Comparator
ARM B
Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:
- Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
- Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
干预措施: Maraviroc (Drug)
结局指标
主要结局
MMC HIV RNA
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective Observational Epidemiologic Study of Maraviroc's SafetyHuman Immunodeficiency VirusNCT00665561ViiV Healthcare2,500
终止
3 期
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1HIV-1NCT01345630ViiV Healthcare813
已完成
2 期
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected PatientsHuman Immunodeficiency Virus-1NCT00827112ViiV Healthcare129
招募中
2 期
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibOvary CancerPeritoneal CancerFallopian Tube CancerNCT05887609University of Colorado, Denver53
已完成
2 期
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1HIV-1 InfectionHIV InfectionsNCT00993148Northwestern University25